false
0001566044
0001566044
2024-09-12
2024-09-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
September 12, 2024
VYNE
Therapeutics Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-38356 |
|
45-3757789 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification Number) |
685
Route 202/206 N., Suite 301
Bridgewater,
New Jersey 08807
(Address of principal executive offices, including
Zip Code)
(800)
775-7936
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name of each exchange
on which registered |
Common
Stock, $0.0001 par value |
|
VYNE |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 8.01 Other Events.
On September 12, 2024, VYNE Therapeutics Inc. issued a press release
entitled “VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor.” A copy
of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
VYNE THERAPEUTICS INC. |
|
|
|
Date: September 12, 2024 |
By: |
/s/ Mutya Harsch |
|
|
Mutya Harsch |
|
|
Chief Legal Officer and General Counsel |
Exhibit 99.1
![](https://www.sec.gov/Archives/edgar/data/1566044/000110465924099121/tm2423851d1_ex99-1img001.jpg)
VYNE Therapeutics Announces Positive Phase 1a SAD Data
for VYN202, a Novel BD2-Selective BET Inhibitor
| · | VYN202 was generally well tolerated with no drug-related adverse events |
| · | Pharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood |
| · | Pharmacodynamic activity observed on target engagement and inflammatory biomarkers |
| · | Dosing has begun in the MAD portion of the trial with results expected in Q4 2024 |
BRIDGEWATER, N.J., September 12, 2024 -- VYNE Therapeutics Inc.
(Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated
therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced positive data from the single
ascending dose (“SAD”) portion of its ongoing Phase 1a trial of VYN202. The Phase 1a trial is a two-part, double-blind, placebo-controlled
dose-escalation study in healthy volunteers consisting of SAD and multiple ascending dose (“MAD”) components to evaluate the
safety, tolerability, pharmacokinetics (“PK”) and pharmacodynamics of VYN202. Findings from the SAD portion of the Phase 1a
trial to date are as follows:
VYN202 Was Generally Well Tolerated Across All Dose Groups
Single ascending doses of VYN202 across all cohorts were
generally well tolerated up to and including the highest planned dose level. There were no serious adverse events, drug-related
adverse events, or clinically significant abnormalities in clinical laboratory results or electrocardiogram findings.
VYN202 Demonstrated Dose-Dependent PK
VYN202 also met expected PK parameters, with plasma and urine drug
concentrations of VYN202 increasing in a dose-dependent manner across all doses tested.
VYN202 Demonstrated Pharmacodynamic Effects
Participant blood samples were stimulated ex-vivo to assess the pharmacodynamic
impact of single doses of VYN202 on key target-engagement and inflammatory biomarkers. Results demonstrated an increase in marker protein
HEXIM1, indicative of target engagement of VYN202 with BET proteins1. Additionally, exploratory data from the SAD arm showed
that single doses of VYN202 demonstrated biological activity and an inhibitory effect on select inflammatory biomarkers relevant to psoriasis
and rheumatoid arthritis.
Phase 1a MAD Portion of Trial Initiated
The primary objectives of the MAD portion of the Phase 1a trial are
to assess safety, tolerability, PK and pharmacodynamics of VYN202 over 14 days at different dose levels. Results are expected in Q4 2024.
“These results from our SAD trial mark the first clinical data
for our BD2-selective BET inhibitor, VYN202, and represent an important milestone for our Company and the development of our BET inhibitor
platform,” said David Domzalski, President and Chief Executive Officer of VYNE. “We look forward to further assessing safety
and PK as well as VYN202’s potential to impact several relevant biomarkers following multiple doses, which we expect to disclose next
quarter. These data would inform the design of our planned studies in psoriasis and rheumatoid arthritis.”
About VYN202
VYN202
is an innovative, oral small molecule BET inhibitor that has potential class-leading selectivity and potency for BD2 vs. BD1. By
maximizing BD2 selectivity, VYNE believes VYN202 has the potential to be a more conveniently administered non-biologic treatment option
for both acute control and chronic management of immuno-inflammatory indications, in which the damaging effects of unrestricted inflammatory
signaling activity is common. VYN202 is structurally distinct from VYNE’s pan-BET inhibitor (VYN201) and covered by distinct Patent
Cooperation Treaty and provisional composition of matter patent applications directed to new chemical entities and their uses.
About BET Inhibitors
BET proteins play a key role in regulating
gene transcription via epigenetic interactions (“reading”). Recent research has identified a key role for these proteins in
regulating activation of immune cells, including T and B cells, and subsequent inflammatory and fibrotic processes. As epigenetic readers,
BET proteins regulate the recruitment of transcriptional factors that are key to the production of several pro-inflammatory cytokines.
BET inhibitors have the potential to treat a range of immuno-inflammatory and fibrotic diseases by blocking pro-inflammatory cytokine
transcription, with additional potential in myeloproliferative neoplastic disorders.
1. Lin, Xiaoyu et al. “HEXIM1 as a Robust Pharmacodynamic Marker
for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues.” Molecular Cancer Therapeutics
vol. 16,2 (2017): 388-396. doi:10.1158/1535-7163.MCT-16-0475.
About VYNE Therapeutics Inc.
VYNE is a clinical-stage biopharmaceutical company focused on developing
differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. VYNE’s unique and proprietary
BET inhibitors, which comprise its InhiBET™ platform, are designed to overcome limitations of early generation BET inhibitors by
leveraging alternative routes of administration and enhanced selectivity.
For
more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its
website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition
to following its press releases, filings with the U.S. Securities and Exchange Commission (“SEC”), public conference calls,
and webcasts.
Cautionary Statement Regarding
Forward-Looking Statements
This release includes
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited
to, statements related to VYNE’s ability to successfully complete the Phase 1a SAD/MAD trial of VYN202 and to receive
favorable results from such trial, as well as the timing of results from the MAD portion of the trial, the role of trial results in
informing the design of planned studies in psoriasis and rheumatoid arthritis and the potential benefits of VYN202. All statements
in this press release which are not historical facts are forward-looking statements. Any forward-looking statements are based on
VYNE’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks,
uncertainties and assumptions that could cause actual results to differ materially and adversely from those set forth or implied by
such forward-looking statements. These risks and uncertainties include, but are not limited to: VYNE’s ability to enroll
patients in its clinical trials and successfully develop its product candidates; VYNE’s ability to complete and receive
favorable results from clinical trials of its product candidates; VYNE’s ability to obtain additional funding, either through
equity or debt financing transactions or collaboration arrangements; and VYNE’s ability to comply with various regulations
applicable to its business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause
VYNE’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk
Factors” in VYNE’s Annual Report on Form 10-K for the year ended December 31, 2023 and VYNE’s other
filings from time to time with the SEC. Although VYNE believes these forward-looking statements are reasonable, they speak only as
of the date of this announcement and VYNE undertakes no obligation to update publicly such forward-looking statements to reflect
subsequent events or circumstances, except as otherwise required by law. Given these risks and uncertainties, you should not rely
upon forward-looking statements as predictions of future events.
Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Tyler
Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@vynetx.com
Media Relations:
Mike Beyer
Sam Brown Inc.
312-961-2502
mikebeyer@sambrown.com
v3.24.2.u1
Cover
|
Sep. 12, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Sep. 12, 2024
|
Entity File Number |
001-38356
|
Entity Registrant Name |
VYNE
Therapeutics Inc.
|
Entity Central Index Key |
0001566044
|
Entity Tax Identification Number |
45-3757789
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
685
Route 202/206 N.
|
Entity Address, Address Line Two |
Suite 301
|
Entity Address, City or Town |
Bridgewater,
|
Entity Address, State or Province |
NJ
|
Entity Address, Postal Zip Code |
08807
|
City Area Code |
800
|
Local Phone Number |
775-7936
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, $0.0001 par value
|
Trading Symbol |
VYNE
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
VYNE Therapeutics (NASDAQ:VYNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
VYNE Therapeutics (NASDAQ:VYNE)
Historical Stock Chart
From Sep 2023 to Sep 2024